• Males or post-menopausal females aged 18 through 65 years at the time of screening.

• Parts A, B, C only: Participants with or without T2DM. If participants have a diagnosis of T2DM, the glucose control managed with diabetes diet and in addition to metformin treatment no more than two treatment options (with a stable dose 3 months prior to screening).

• Part D only: Participants who are diagnosed with T2DM, have inadequate glycaemic control with diet and exercise. Participants who are prescribed an oral anti-diabetic agent such as metformin, a DPP IV inhibitor, sulphonylurea, glinides, alphaglucosidase inhibitors, and an SGLT2 inhibitor may be eligible to enter the study following a washout of 4-weeks or 5-half lives (whichever is longer) washout period.

• Participants with a screening HbA1c value within the target range of

‣ ≥ 42 to ≤ 75 mmol/mol (6% to 9%) for T2DM patients

⁃ \< 48 mmol/mol (\< 6.5%) for participants without T2DM

• Body mass index from ≥27 (≥25 in Part D) to ≤39.9 kg/m2 (inclusive).

• Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

• Written informed consent and any locally required authorization (eg, European Union Data Privacy Directive) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations

• Ability to complete and meet all eligibility requirements for randomisation within 60 days after signing the ICF.

• Venous access suitable for multiple cannulations.

• Willing and able to self-administer weekly SC injections (Parts C and D only).